GSK and Merck have initiated a Phase I trial to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA(pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumor(s) that have progressed after standard treatment.   GSK3174998 is a humanized IgG1 anti-OX40 monoclonal antibody identified through a collaboration with MD Anderson Cancer Center. OX40 is a tumor necrosis factor receptor that results...